AEON Biopharma reports Q2 2026 cash $3.4M, completes $15.3M offering, FDA Type 2b expected

AEON Biopharma, Inc.

Q2 2026 cash and equivalents $3.4M as of June 30, 2026; excludes ~$13.6M net proceeds from July public offering.
Completed $15.3M underwritten offering in July 2026; milestone warrants could add $34.0M gross; cash runway into Q1 2027.
FDA BPD Type 2a meeting in Q1 2026 supported ABP-450 analytical approach; Type 2b feedback expected H2 2026.
Regained NYSE American compliance on Aug 3, 2026.
Presented comparability data at AAN (April) and AHS (June) meetings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.